Company Overview

TG Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of therapies for B-cell diseases, particularly autoimmune and hematologic conditions. The company operates within the biotechnology and specialty pharmaceutical industries and is primarily known for its work in multiple sclerosis (MS) and B-cell malignancies. Its core commercial product is Briumvi (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for relapsing forms of multiple sclerosis. Historically, the company also developed oncology-focused therapies targeting chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

TG Therapeutics’ principal revenue driver is product sales associated with Briumvi, alongside collaboration-related revenue and prior licensing arrangements. The company has positioned itself around differentiated B-cell targeting therapies, emphasizing shorter infusion times and commercial specialization in neurology. Founded in 1993 and later reoriented through strategic acquisitions and licensing activities, TG Therapeutics evolved from an oncology-centered biotechnology company into a commercial-stage MS-focused enterprise following regulatory approvals and pipeline reprioritization.

Business Operations

TG Therapeutics generates revenue primarily through its Briumvi franchise and associated commercialization activities in the United States. The company’s operations historically included two principal therapeutic areas: hematologic oncology and autoimmune disease, although recent strategic emphasis has shifted strongly toward neurology and immunology. The company controls intellectual property and development rights tied to ublituximab and related combination therapies, supported by clinical development, regulatory, medical affairs, and commercial infrastructure concentrated in the U.S. market.

The company operates principally in the United States but has pursued international expansion through partnerships and licensing arrangements. TG Therapeutics previously maintained collaborations involving therapies such as umbralisib and ublituximab in global markets. Its operational model relies heavily on clinical development capabilities, regulatory execution, and targeted specialty commercialization rather than large-scale manufacturing ownership. Manufacturing and supply chain activities are supported through third-party contract manufacturers and service providers common within the biotechnology sector.

Strategic Position & Investments

TG Therapeutics’ strategic direction centers on expanding the commercial adoption of Briumvi in relapsing multiple sclerosis while evaluating lifecycle management opportunities and additional indications involving B-cell modulation. The company has invested substantially in commercialization infrastructure, physician outreach, payer access, and post-approval clinical development. Its competitive positioning in MS is based partly on infusion efficiency, anti-CD20 therapeutic efficacy, and pricing dynamics relative to competing monoclonal antibody therapies.

The company has also pursued strategic restructuring initiatives to prioritize capital allocation toward neurology-focused growth. Earlier oncology programs, including umbralisib-related initiatives, were reduced or discontinued following regulatory and clinical developments. TG Therapeutics continues to evaluate pipeline opportunities involving autoimmune and neuroimmunology applications. While the company does not maintain a broad subsidiary portfolio comparable to large pharmaceutical conglomerates, its value proposition is closely tied to proprietary biologic assets, regulatory exclusivity, and specialized commercialization expertise.

Geographic Footprint

TG Therapeutics is headquartered in Morrisville, North Carolina, with operations concentrated primarily in the United States. Its commercial activities are heavily U.S.-focused due to the domestic launch and distribution of Briumvi, though the company has historically explored international commercialization opportunities through partnerships and licensing arrangements in select markets outside North America.

The company’s broader operational influence extends into parts of Europe and other international regions through clinical trial activity, intellectual property management, manufacturing relationships, and prior collaborative agreements. However, compared with multinational pharmaceutical companies, TG Therapeutics maintains a relatively focused geographic footprint centered on the U.S. specialty neurology market.

Leadership & Governance

TG Therapeutics is led by executives with backgrounds in biotechnology commercialization, clinical development, and capital markets. The company’s governance structure reflects its transition from a development-stage biotechnology company into a commercial-stage pharmaceutical organization. Leadership has consistently emphasized focused execution in B-cell disease therapeutics, disciplined capital allocation, and expansion within neuroimmunology markets.

Key executives include:

• Michael S. Weiss – Executive Chairman and Chief Executive Officer
• Sean A. Power – Chief Financial Officer
• Tarcisio F. de Oliveira, M.D. – Chief Medical Officer
• Jelena Mrdjenovich – Chief Commercial Officer
• Adam S. Cutler – General Counsel and Corporate Secretary

The company’s leadership philosophy has emphasized concentrated therapeutic specialization rather than diversification across numerous disease categories. Public filings and investor communications indicate a strategic focus on commercial execution, regulatory compliance, and maximizing the long-term value of its anti-CD20 platform.